Literature DB >> 16796815

MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors.

D C Jinga1, A Blidaru, Ileana Condrea, Carmen Ardeleanu, Cristina Dragomir, G Szegli, Maria Stefanescu, Cristiana Matache.   

Abstract

The goal of our study was to analyse the prognostic values for some matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in breast cancer. We evaluated the activity and the expression levels of MMP-9, MMP-2, TIMP-1 and TIMP-2 in malignant versus benign fresh breast tumor extracts. For this purpose, gelatinzymography, immunoblotting and ELISA were used to analyse the activity and expression of MMPs and TIMPs. We found that MMP-9 expression level and activity are increased in malignant tumors. In addition, MMP-9/TIMP-1 and MMP-2/TIMP-2 ratio values obtained by us were significantly different in malignant tumors compared to benign tumors. We suggest that the abnormal MMP-9/TIMP-1 balance plays a role in the configuration of breast invasive carcinoma of no special type and also in tumor growth, while altered MMP-2/TIMP-2 ratio value could be associated with lymph node invasion and used as a prognostic marker in correlation with Nottingham Prognostic Index. Finally, we showed that in malignant tumors high expression of estrogen receptors is associated with enhanced activity of MMP-2 and increased bcl- 2 levels, while high expression of progesterone receptors is correlated with low TIMP-1 protein levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16796815      PMCID: PMC3933137          DOI: 10.1111/j.1582-4934.2006.tb00415.x

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  51 in total

1.  Proteolytic imbalance is reversed after therapeutic surgery in breast cancer patients.

Authors:  Gianluigi Giannelli; Roberta Erriquez; Emilia Fransvea; Antonella Daniele; Paolo Trerotoli; Francesco Schittulli; Maria Grano; Michele Quaranta; Salvatore Antonaci
Journal:  Int J Cancer       Date:  2004-05-01       Impact factor: 7.396

Review 2.  ABC of breast diseases. Prognostic factors.

Authors:  W R Miller; I O Ellis; J R Sainsbury; J M Dixon
Journal:  BMJ       Date:  1994-12-10

Review 3.  Activation mechanisms of matrix metalloproteinases.

Authors:  H Nagase
Journal:  Biol Chem       Date:  1997 Mar-Apr       Impact factor: 3.915

Review 4.  Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999.

Authors:  P L Fitzgibbons; D L Page; D Weaver; A D Thor; D C Allred; G M Clark; S G Ruby; F O'Malley; J F Simpson; J L Connolly; D F Hayes; S B Edge; A Lichter; S J Schnitt
Journal:  Arch Pathol Lab Med       Date:  2000-07       Impact factor: 5.534

5.  Proteolysis in human breast cancer.

Authors:  E A Garbett; M W Reed; T J Stephenson; N J Brown
Journal:  Mol Pathol       Date:  2000-04

Review 6.  Tissue inhibitor of metalloproteinases-1 in breast cancer.

Authors:  S Ø Würtz; A-S Schrohl; N Møller Sørensen; U Lademann; I J Christensen; H Mouridsen; N Brünner
Journal:  Endocr Relat Cancer       Date:  2005-06       Impact factor: 5.678

7.  Different expression patterns of MMP-2 and MMP-9 in breast cancer.

Authors:  S Y Rha; W I Yang; J H Kim; J K Roh; J S Min; K S Lee; B S Kim; H C Chung
Journal:  Oncol Rep       Date:  1998 Jul-Aug       Impact factor: 3.906

8.  ERbeta exerts multiple stimulative effects on human breast carcinoma cells.

Authors:  Yi-Feng Hou; Sheng-Tao Yuan; He-Cheng Li; Jiong Wu; Jin-Song Lu; Gang Liu; Li-Juan Lu; Zhen-Zhou Shen; Jian Ding; Zhi-Ming Shao
Journal:  Oncogene       Date:  2004-07-29       Impact factor: 9.867

9.  Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer.

Authors:  A G Remacle; A Noël; C Duggan; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

10.  Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.

Authors:  A Scorilas; A Karameris; N Arnogiannaki; A Ardavanis; P Bassilopoulos; T Trangas; M Talieri
Journal:  Br J Cancer       Date:  2001-06-01       Impact factor: 7.640

View more
  47 in total

1.  Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element.

Authors:  Karl E Miletti-González; Kyle Murphy; Muthu N Kumaran; Abhilash K Ravindranath; Roman P Wernyj; Swayamjot Kaur; Gregory D Miles; Elaine Lim; Rigel Chan; Marina Chekmareva; Debra S Heller; David Foran; Wenjin Chen; Michael Reiss; Elisa V Bandera; Kathleen Scotto; Lorna Rodríguez-Rodríguez
Journal:  J Biol Chem       Date:  2012-03-20       Impact factor: 5.157

Review 2.  Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumorigenesis.

Authors:  Laura Kass; Janine T Erler; Micah Dembo; Valerie M Weaver
Journal:  Int J Biochem Cell Biol       Date:  2007-07-19       Impact factor: 5.085

Review 3.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

Review 4.  Building a bridge to recovery: the pathophysiology of LVAD-induced reverse modeling in heart failure.

Authors:  Shigeru Miyagawa; Koichi Toda; Teruya Nakamura; Yasushi Yoshikawa; Satsuki Fukushima; Shunsuke Saito; Daisuke Yoshioka; Tetsuya Saito; Yoshiki Sawa
Journal:  Surg Today       Date:  2015-04-04       Impact factor: 2.549

5.  Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.

Authors:  Marilena Tauro; Gemma Shay; Samer S Sansil; Antonio Laghezza; Paolo Tortorella; Anthony M Neuger; Hatem Soliman; Conor C Lynch
Journal:  Mol Cancer Ther       Date:  2017-01-09       Impact factor: 6.261

6.  Prognostic value of matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9) and aminopeptidase N/CD13 in breast cancer patients.

Authors:  Irena Ranogajec; Jasminka Jakić-Razumović; Velibor Puzović; Jelka Gabrilovac
Journal:  Med Oncol       Date:  2011-05-25       Impact factor: 3.064

7.  Plasma levels of matrix metalloproteinases 2 and 9 correlate with histological grade in breast cancer patients.

Authors:  Fortunata Vasaturo; Fabiana Solai; Carolina Malacrino; Tiziana Nardo; Bruno Vincenzi; Mauro Modesti; Susanna Scarpa
Journal:  Oncol Lett       Date:  2012-10-17       Impact factor: 2.967

8.  Effects of an Engineered Anti-HER2 Antibody chA21 on Invasion of Human Ovarian Carcinoma Cell In Vitro.

Authors:  Yi Gao; Qiang Wu; Zheng-Sheng Wu; Gui-Hong Zhang; An-Li Zhang
Journal:  Chin J Cancer Res       Date:  2011-06       Impact factor: 5.087

9.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  Differential matrix rigidity response in breast cancer cell lines correlates with the tissue tropism.

Authors:  Ana Kostic; Christopher D Lynch; Michael P Sheetz
Journal:  PLoS One       Date:  2009-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.